People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Hexamer Therapeutics, Inc | — | Biotechnology | Pre-Seed | $1.1M | $4.1M | 2024 |
R. SCOTT H BLACKLEY at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside R. SCOTT H BLACKLEY on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ROBERT H BOGDEN | 1 | 1 |
| KEITH H MILLER | 1 | 1 |
| COLIN H COLLINS | 1 | 1 |
| STEPHEN H CRAWFORD | 1 | 1 |
| Keith David Miller | 1 | 1 |
| Robert Hale Bogden | 1 | 1 |
| Colin Conrad Collins | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.